Foster Victor Wealth Advisors 13F: Adds $1.2M to GSK Stake
Key Points
- Foster Victor Wealth Advisors increased its stake in GSK plc by 5.8%, purchasing an additional 23,934 shares to end with 438,220 shares.
- GSK plc is scheduled to release its next earnings report on October 28, 2026, following a trailing twelve-month revenue of $33.2 billion.
- Other major institutional investors adjusted their positions, with Dodge & Cox reducing its holdings while Fisher Asset Management added shares.
Since the filing, $GSK is up 2.1% to date (from the $50.02 close on Oct 21, 2026).
Get GSK plc text alerts
We text you when insiders, Congress, analysts or big funds move on $GSK.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated GSK plc alert may contain errors. Disclosures
Foster Victor Wealth Advisors increased its holdings in GSK plc (GSK) by 5.8%, purchasing an additional 23,934 shares during the period. The move was disclosed in a Form 13F filing with the SEC on October 21, 2026. GSK plc shares closed at $50.02 on the day of the filing.
GSK
GSK plc
What Changed in Foster Victor Wealth Advisors's GSK Position
With this addition, Foster Victor Wealth Advisors brought its total stake in the drug maker to 438,220 shares. The reported value of the position stood at $21,674,353 based on the filing details. The firm previously held 414,286 shares of the company.
Other Institutional Activity in GSK
Other large funds also adjusted their positions in the healthcare company. Dodge & Cox reduced its holdings by 9,854,995 shares, ending with 58,662,974 shares valued at roughly $3.1 billion. Dodge & Cox Inc. cut its stake by 10,465,478 shares to finish with 48,197,514 shares worth $2,453,735,430. Fisher Asset Management, LLC grew its position by 1,201,346 shares to hold 35,722,792 shares valued at $1,818,647,335. Primecap Management Company trimmed its stake by 22,684 shares, leaving it with 25,182,068 shares worth $1,282,019,078. JTC Employer Solutions Trustee Ltd. lowered its holdings by 449,407 shares to end with 8,592,987 shares valued at $437,468,966.
GSK plc Stock Up 1.0%
GSK shares recently traded around $50.54, up about 1.0% since the filing date. The stock has a market value near $102.0 billion and trades below its 200-day moving average of $52.35 while sitting above its 50-day moving average of $49.54.
Recent Earnings
GSK plc operates in the healthcare sector, focusing on the research and manufacture of vaccines and medicines. The company is set to report its next earnings on October 28, 2026. Its trailing twelve-month earnings per share sit at $3.17.
Dividend
GSK pays an annual dividend rate of $1.82 per share, which gives the stock a dividend yield of 3.63%.
About GSK
Based in London, United Kingdom, GSK plc researches, develops, and distributes vaccines, specialty medicines, and general treatments globally. The firm operates through commercial operations and research and development segments to address various medical conditions.
Bottom Line
Investors will watch for upcoming earnings results on October 28, 2026, to gauge the company's financial health. Institutional filings continue to show shifting sentiment among large asset managers as the stock trades near its moving averages.
Related Filing Alerts
Source: Foster Victor Wealth Advisors's 13F filing on $GSK (Oct 21, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts